The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
Teijin Pharma Bets on Ascendis Rare Disease Assets as Feburic Sales Crumble
With sales of its gout treatment Feburic (febuxostat) collapsing, Teijin Pharma is fast-tracking a business overhaul. President Masaki Taneda said the company will pivot to rare and intractable diseases, with three in-licensed drugs from Denmark’s Ascendis Pharma set to anchor…
To read the full story
Related Article
- Teijin Debuts Yorvipath in Japan, Eyes Rare Disease Growth
November 7, 2025
- Teijin Earns Japan Rights to 3 Hormone Therapies from Denmark’s Ascendis
November 30, 2023
- Teijin Pharma Plans Pivot to Rare Diseases as Generics Eat into Feburic Sales
March 15, 2023
BUSINESS
- iPark Institute to Launch AI-Based Platform to Link Investors with Startups
January 16, 2026
- Acromegaly Drug Palsonify Meets Primary Endpoint in Japan PII/PIII Trial
January 16, 2026
- Tanabe’s EPP/XLP Drug Hits Main Goals in PIII, Weighs Launch Strategy
January 16, 2026
- Forxiga Generics Reach 11% Share in First Month: Intage
January 16, 2026
- Takeda to Halt Sales of Cell Therapy Alofisel in Japan
January 15, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…